DTPA-Dextran Radiolabeling Kit for Sentinel Node Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sentinel node biopsy techniques for cancer diagnosis lack standardized radiopharmaceutical agents with optimal properties for rapid injection site clearance and low distal lymph node accumulation, leading to inconsistent results and high false-negative rates.
Innovation Solution
A composition of dextran conjugated with a bifunctional chelating agent, DTPA, is developed, which achieves high radiochemical purity and stability when radiolabeled with 99mTc, using a pH-buffered diluent and reducing agents to enhance radiolabeling efficiency and patient comfort, forming a stable and efficient diagnostic imaging agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current off-label radiopharmaceutical agents (99mTc-sulfur colloid, filtered 99mTc-sulfur colloid, 99mTc-antimony trisulfide, 99mTc-labeled albumin microcolloids) are used for sentinel node biopsy, then the procedure can be performed, but the agents lack optimal properties for rapid injection site clearance and high sentinel node extraction, resulting in inconsistent results and high false-negative rates
Solution Approach 1:
The patent modifies the chemical structure of DTPA by conjugating it to dextran with specific molecular weight ranges (10,000-100,000 Daltons) and controlling the degree of substitution. This parameter optimization achieves rapid injection site clearance and high sentinel node extraction efficiency, resolving the reliability issue while maintaining ease of manufacture through standardized kit formulation.
Solution Approach 2:
The invention creates a composite radiopharmaceutical by conjugating the chelating agent DTPA with dextran polymer. This composite structure combines the metal-binding capability of DTPA with the favorable pharmacokinetic properties of dextran, achieving both rapid clearance and high node extraction that neither component alone provides, thereby improving detection accuracy.
2Reliability
If free DTPA is used to coordinate heavy metal ions like 111Indium as an octadentate ligand, then high binding stability is achieved, but when binding 99mTc ions, the heptadentate configuration shows decreased thermodynamic stability, making it susceptible to competition and resulting in decreased radiochemical purity
Solution Approach 1:
The patent introduces a transchelating agent as an intermediary substance that facilitates the transfer of 99mTc from the unstable free DTPA complex to the stable DTPA-dextran conjugate. This intermediary mechanism resolves the thermodynamic stability issue by providing a stepwise chelation process that maintains high radiochemical purity despite the inherent instability of heptadentate 99mTc-DTPA binding.
3Reliability
If a standardized radiopharmaceutical agent is developed for sentinel node detection, then detection accuracy and consistency improve, but the complexity of formulation and radiolabeling procedures increases
Solution Approach 1:
The patent prepares the DTPA-dextran conjugate in advance and formulates it as a stable lyophilized powder in a kit. This preliminary action allows the complex molecule to be pre-synthesized and quality-controlled, then simply reconstituted with 99mTc-sodium pertechnetate at the time of use. This approach maintains high detection consistency while minimizing procedural complexity during actual sentinel node biopsy procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a high radiochemical purity of 99mTc-DTPA-dextran with rapid injection site clearance and low distal lymph node accumulation, improving sentinel node detection and patient comfort through a stable and efficient diagnostic imaging agent.
Implementation Method 1
the bifunctional ligand, DTPA, which are conjugated to a number of amino-terminated leashes on to a dextran molecule via an amide bond... coordinates all five of its deprotonated carboxylic groups to bind to heavy metal ions, such as, for example, 111Indium... the heptadentate DTPA binds with decreased thermodynamic stability
Implementation Method 2
identifying the ideal transchelator, Glycine (which also serves as a pH buffer), and utilizing the following facts: (1) the distribution of competing ligands for 99mTc is determined by association rate constants, and (2) the dissociation rate constants for 99mTc from its DTPA-dextran complex is very slow and pH-dependent. Hence, the high efficiency of radiolabeling DTPA-dextran is enhanced by the transient binding to Glycine under highly acidic conditions, Glycine transferring the radioisotope to DTPA-dextran
Implementation Method 3
The present disclosure further provides a reducing agent, such as, for example, L-ascorbic acid, which further stabilizes a radiolabeled DTPA-dextran preparation containing excess stannous or stannic ions, preventing the formation of Sn-colloids or other radiochemical impurities, such as, Sn4+
Data Source
AI summary
The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce 99mTc-pertechnetate, Ascorbic Acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-Trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and Glycine to transchelate Technetium-99m under highly acidic conditions to facilitate radiolabeling DTPA-dextran with high radiochemical purity. In addition, the invention pertains to methods for making and using the compositions. The reconstitution of the lyophilized composition by 99mTc-pertechnetate, resulting in radiolabeled 99mTc-DTPA-dextran in a composition between pH 3 to 4. This invention contains a Diluent vial, which when used will shift the pH to a moderately acidic pH, which would provide less pain on injection and ease-of-use to clinical practioners for adjusting its potency.